Using advanced imaging to predict how lung cancer patients respond to immunotherapy
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11062429
This study is looking at how new ways of analyzing CT scans can help doctors figure out which lung cancer patients are likely to benefit from immunotherapy, so they can create more personalized treatment plans that work better for each individual.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11062429 on ClinicalTrials.gov |
What this research studies
This research investigates how novel radiomics, which involves analyzing imaging data from CT scans, can help predict which lung cancer patients will respond favorably to immunotherapy treatments. By developing new computer vision techniques, the study aims to identify predictive biomarkers that can better select patients for these costly therapies, potentially improving treatment outcomes. The approach seeks to address the limitations of current methods that rely on tumor size changes, which may not accurately reflect a patient's response to treatment. This research could lead to more personalized treatment plans for patients with non-small cell lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are being considered for immunotherapy treatments.
Not a fit: Patients with lung cancer who are not eligible for immunotherapy or those with other types of cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the ability to identify lung cancer patients who are most likely to benefit from immunotherapy, potentially leading to better treatment outcomes and reduced healthcare costs.
How similar studies have performed: Other research has shown promise in using advanced imaging techniques to predict treatment responses in cancer, suggesting that this approach could be a valuable advancement in the field.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MADABHUSHI, ANANT — EMORY UNIVERSITY
- Study coordinator: MADABHUSHI, ANANT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.